Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

International Parkinson and Movement Disorder Society
Main Content

PKAN Disease Rating Scale (PKAN-DRS)

MDS-UPDRS

PKAN Disease Rating Scale (PKAN-DRS)


Acronym: PKAN-DRS

Authors: Alejandra Darling, Cristina Tello, Marıa Josep Martı, Cristina Garrido, Sergio Aguilera-Albesa, Miguel Tomas Vila, Itziar Gaston, Marcos Madruga, Luis Gonzalez Gutierrez, Julio Ramos Lizana, Montserrat Pujol, Tania Gavilan Iglesias, Kylee Tustin, Jean Pierre Lin, Giovanna Zorzi, Nardo Nardocci, Loreto Martorell, Gustavo Lorenzo Sanz, Fuencisla Gutierrez, Pedro J. Garcıa, Lidia Vela, Carlos Hernandez Lahoz, Juan Darıo Ortigoza Escobar, Laura MartíSanchez, Fradique Moreira, Miguel Coelho, Leonor Correia Guedes, Ana Castro Caldas, Joaquim Ferreira, Paula Pires, Cristina Costa, Paulo Rego, Marina Magalhaes, María Stamelou, Daniel Cuadras Palleja, Carmen Rodríguez-Blázquez, Pablo Martínez-Martín, Vincenzo Lupo, Leonidas Stefanis, Roser Pons, Carmen Espinos, Teresa Temudo, and Belén Perez Dueñas

The PKAN Disease Rating Scale (PKAN-DRS) was developed to assess domains of cognition, behavior, and disability with scores based on neurological assessment of dystonia, parkinsonism, and other neurological signs in patients with pantothenate kinase-associated neurodegeneration (PKAN).

Original Publication View the Scale (PDF)

To request permission to use this Rating Scale, please fill out a Permission Request Form.

Year Published: 2017

Last Updated: Unchanged since publication

Assessment Type: ClinRO

Estimated Time to Complete: 10-15 minutes

Available Translations: None

Additional Scale Publications:

Marshall RD, Collins A, Escolar ML, Jinnah H, Klopstock T, Kruer MC, Videnovic A, Robichaux‐Viehoever A, Swett L, Revicki DA, Bender RH and Lenderking WR. A scale to assess activities of daily living in Pantothenate Kinase‐Associated Neurodegeneration. Movement Disorders Clinical Practice 2019 Feb; 6(2) 139-149.

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice